TECH - Bio-Techne Corporation

NasdaqGS - NasdaqGS Real-time price. Currency in USD

Bio-Techne Corporation

614 McKinley Place N.E.
Minneapolis, MN 55413
United States
612 379 8854

Full-time employees3,000

Key executives

NameTitlePayExercisedYear born
Mr. Charles R. KummethCEO, Pres & Director5.07M31.64M1960
Mr. James T. HippelExec. VP of Fin. & CFO1.94M15.16M1971
Mr. Kim KeldermanPres of Diagnostics & Genomics1.35M699.55k1967
Mr. William A. GeistPres of Protein Sciences Segment904.2kN/A1970
David ClairSr. Director of Investor Relations & Corp. Devel.N/AN/AN/A
Mr. Shane BohnenSr. VP, Gen. Counsel & Corp. Sec.N/AN/AN/A
Mr. Gerry AndrosVP of Sales and MarketingN/AN/AN/A
Mr. Robert M. GavinVP of Corp. Devel.N/AN/A1968
Ms. Brenda S. EversonSr. VP & Chief HR OfficerN/AN/AN/A
Mr. Luca CicchettiManaging DirectorN/AN/AN/A
Amounts are as of 31 December 2022, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.


Bio-Techne Corporation, together with its subsidiaries, develops, manufactures, and sells life science reagents, instruments, and services for the research and clinical diagnostic markets worldwide. The company operates through two segments, Protein Sciences, and Diagnostics and Genomics. The Protein Sciences segment develops and manufactures biological reagents used in various aspects of life science research, diagnostics, and cell and gene therapy, such as cytokines and growth factors, antibodies, small molecules, tissue culture sera, and cell selection technologies. This segment also offers proteomic analytical tools for automated western blot and multiplexed ELISA workflow consists of manual and automated protein analysis instruments and immunoassays for use in quantifying proteins in various biological fluids. The Diagnostics and Genomics segment develops and manufactures diagnostic products, including controls, calibrators, and diagnostic assays for regulated diagnostics market, exosome-based molecular diagnostic assays, advanced tissue-based in-situ hybridization assays for spatial genomic and tissue biopsy analysis, and genetic and oncology kits for research and clinical applications; and sells products for genetic carrier screening, oncology diagnostics, molecular controls, and research, as well as instruments and process control products for hematology, blood chemistry and gases, and coagulation controls and reagents used in various diagnostic applications. It has strategic partnership with Lunaphore Technologies S.A. to develop automated same-slide spatial multiomics solution. The company was formerly known as Techne Corporation and changed its name to Bio-Techne Corporation in November 2014. Bio-Techne Corporation was founded in 1976 and is headquartered in Minneapolis, Minnesota.

Corporate governance

Bio-Techne Corporation’s ISS governance QualityScore as of 1 June 2023 is 7. The pillar scores are Audit: 10; Board: 6; Shareholder rights: 1; Compensation: 9.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.